Evidence map›Paper›PMID 19969019›Full record

ArticleNeurotoxicology2010

Endocannabinoid signaling in neurotoxicity and neuroprotection.

C Pope, R Mechoulam, L Parsons

Abstract read
In one paragraph

Article in Neurotoxicology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Safety and Toxicology of Cannabinoids.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

C PopeCenter for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK, USA. carey.pope@okstate.edu
R Mechoulam
L Parsons
Hebrew University of Jerusalem · ILOklahoma State University · USScripps Research Institute · US

Funding

Viral Vector CoreP60AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ERIC P ZORRILLA · 2003 to 2026
$46.3M
SYNTHESIS OF SR141716A AND ANANDAMIDE ANALOGSP01DA009789 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI CRAVATT, BENJAMIN F · 1995 to 2013
$11.6M
PRESYNAPTIC MODULATION OF ANTICHOLINESTERASE TOXICITYR01ES009119 · NIEHS · UNIVERSITY OF LOUISIANA AT MONROE · PI POPE, CAREY N · 1998 to 2013
$3.8M
CB1 Modulation of Opioid Peptides and Ethanol IntakeR01AA014619 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI PARSONS, LOREN H. · 2004 to 2008
$1.7M
NIAAA NIH HHS P60 AA006420NIAAA NIH HHS R01 AA014619NIDA NIH HHS DA-9789NIDA NIH HHS P01 DA009789NIEHS NIH HHS R01 ES009119
6 · The paper itself

Abstract

The cannabis plant and products produced from it, such as marijuana and hashish, have been used for centuries for their psychoactive properties. The mechanism for how Delta(9)-tetrahydrocannabinol (THC), the active constituent of cannabis, elicits these neurological effects remained elusive until relatively recently, when specific G-protein coupled receptors were discovered that appeared to mediate cellular actions of THC. Shortly after discovery of these specific receptors, endogenous ligands (endocannabinoids) were identified. Since that time, an extensive number of papers have been published on the endocannabinoid signaling system, a widespread neuromodulatory mechanism that influences neurotransmission throughout the nervous system. This paper summarizes presentations given at the 12th International Neurotoxicology Association meeting that described the potential role of endocannabinoids in the expression of neurotoxicity. Dr. Raphael Mechoulam first gave an overview of the discovery of exogenous and endogenous cannabinoids and their potential for neuroprotection in a variety of conditions. Dr. Larry Parsons then described studies suggesting that endocannabinoid signaling may play a selective role in drug reinforcement. Dr. Carey Pope presented information on the role that endocannabinoid signaling may have in the expression of cholinergic toxicity following anticholinesterase exposures. Together, these presentations highlighted the diverse types of neurological insults that may be modulated by endocannabinoids and drugs/toxicants which might influence endocannabinoid signaling pathways.

Indexed as

EndocannabinoidsAnimalsCannabinoid Receptor ModulatorsHumansNeuroprotective AgentsNeurotoxicity SyndromesReceptors, CannabinoidSignal TransductionCannabinoid Receptor ModulatorsEndocannabinoidsNeuroprotective AgentsReceptors, Cannabinoid

Identifiers

PMID19969019
PMCPMC2891218
OpenAlexW2023853560

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.